ARTÍCULO

Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

Autores: Vásquez Durán, Marcos Antonio; Fioravanti, Jessica; Aranda Vega, Fernando; Paredes, V.; Gomar Peláez, Celia; Ardaiz Iriarte, Nuria María; Fernández Ruiz, Verónica; Méndez, M.; Nistal Villan, Estanislao; Larrea Leoz, María Esther; Gao, Q.; González Aseguinolaza, Gloria; Prieto Valtueña, Jesús María; Berraondo López, Pedro
Título de la revista: ONCOIMMUNOLOGY
ISSN: 2162-402X
Volumen: 5
Número: 8
Páginas: e1196309
Fecha de publicación: 2016
Resumen:
Scavenger receptor class B type I (SR-B1) binds pathogen-associated molecular patterns participating in the regulation of the inflammatory reaction but there is no information regarding potential interactions between SR-B1 and the interferon system. Herein, we report that SR-B1 ligands strongly regulate the transcriptional response to interferon ¿ (IFN¿) and enhance its antiviral and antitumor activity. This effect was mediated by the activation of TLR2 and TLR4 as it was annulled by the addition of anti-TLR2 or anti-TLR4 blocking antibodies. In vivo, we maximized the antitumor activity of IFN¿ co-expressing in the liver a SR-B1 ligand and IFN¿ by adeno-associated viruses. This gene therapy strategy eradicated liver metastases from colon cancer with reduced toxicity. On the other hand, genetic and pharmacological inhibition of SR-B1 blocks the clathrin-dependent interferon receptor recycling pathway with a concomitant reduction in IFN¿ signaling and bioactivity. This effect can be applied to enhance cancer immunotherapy with oncolytic viruses. Indeed, SR-B1 antagonists facilitate replication of oncolytic viruses amplifying their tumoricidal potential. In conclusion, SR-B1 agonists behave as IFN¿ enhancers while SR-B1 inhibitors dampen IFN¿ activity. These results demonstrate that SR-B1 is a suitable pharmacology target to enhance cancer immunotherapy based on IFN¿ and oncolytic viruses.